Novo Nordisk India Sees 52% Sales Jump After Up to 60% Insulin Price Cuts
Novo Nordisk India cut insulin prices by up to 60%, driving a 52% jump in local quarterly sales and lifting its insulin market share to 25%. Unit volumes rose 40% year-over-year, signaling stronger patient access after the pricing adjustments.
1. Price Cut Initiative
In early 2026, Novo Nordisk India implemented price reductions of up to 60% across its insulin portfolio, with an average cut of approximately 45%. The move aimed to enhance affordability and compete more effectively with local generic alternatives.
2. Sales Growth and Market Share
Following the cuts, quarterly sales in India surged 52% year-over-year, while unit volumes climbed 40%. Insulin market share expanded from 18% to 25%, underscoring the strategy’s success in boosting local demand.
3. Margin Impact and Outlook
Although net margins narrowed by about 2 percentage points in the region, management views the reduction as a strategic investment in patient reach. The company plans to monitor profitability and may apply selective price adjustments in other emerging markets.